Literature DB >> 24648824

Evaluation of Defined Daily Dose, percentage of British National Formulary maximum and chlorpromazine equivalents in antipsychotic drug utilization.

Waleed M Sweileh1, Jihad Bani Odeh1, Naser Y Shraim1, Sa'ed H Zyoud1, Ansam F Sawalha1, Samah W Al-Jabi1.   

Abstract

OBJECTIVE: The present study was carried out to investigate and compare the three methods for calculating total antipsychotic dose among outpatients with schizophrenia attending primary psychiatric health care centers. The three methods were: Defined Daily Doses (DDDs), chlorpromazine equivalents (CPZeq) and percentages of the British National Formulary (BNF) maximum.
METHODOLOGY: Antipsychotic drug dosing data for 250 patients with schizophrenia were investigated by calculating Spearman's rank correlation coefficients. Factors associated with antipsychotic dose, expressed as DDDs, CPZeq and percentages of the BNF maximum recommended daily dose, were investigated by means of linear regression analysis.
RESULTS: Spearman's correlation showed that there is a significant relationship between all pairs of the three dosing methods. In all three methods, coherence was strongest when dealing with first generation antipsychotics (FGA). Linear regression analyses showed a high degree of coherence between antipsychotic doses expressed as DDDs, CPZeq and percentages of the BNF maximum recommended daily dose.
CONCLUSION: All three tested methods are reliable and coherent for calculating antipsychotic dosing.

Entities:  

Keywords:  %BNFmax, percentage of British National Formulary maximum; Antipsychotics; CPZeq, chlorpromazine equivalents; Chlorpromazine equivalents; DDD, Defined Daily Dose (DDD); Defined Daily Doses; FGA, first generation antipsychotics; SGA, second generation antipsychotics; Schizophrenia

Year:  2013        PMID: 24648824      PMCID: PMC3950502          DOI: 10.1016/j.jsps.2013.03.003

Source DB:  PubMed          Journal:  Saudi Pharm J        ISSN: 1319-0164            Impact factor:   4.330


  15 in total

1.  Comparative doses and costs of antipsychotic medication.

Authors:  J M Davis
Journal:  Arch Gen Psychiatry       Date:  1976-07

Review 2.  Guidelines for the dosage of neuroleptics. I: Chlorpromazine equivalents of orally administered neuroleptics.

Authors:  M J Rey; P Schulz; C Costa; P Dick; R Tissot
Journal:  Int Clin Psychopharmacol       Date:  1989-04       Impact factor: 1.659

Review 3.  The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.

Authors:  Robert W Buchanan; Julie Kreyenbuhl; Deanna L Kelly; Jason M Noel; Douglas L Boggs; Bernard A Fischer; Seth Himelhoch; Beverly Fang; Eunice Peterson; Patrick R Aquino; William Keller
Journal:  Schizophr Bull       Date:  2009-12-02       Impact factor: 9.306

4.  Clinical and social determinants of psychotropic drug prescription for schizophrenia outpatients in China.

Authors:  Yu-Tao Xiang; Yong-Zhen Weng; Chi-Ming Leung; Wai-Kwong Tang; Gabor Sandor Ungvari; Jozsef Gerevich
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2007-01-16       Impact factor: 5.067

5.  Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose.

Authors:  J P McEvoy; G E Hogarty; S Steingard
Journal:  Arch Gen Psychiatry       Date:  1991-08

6.  Clinical and social correlates with the use of depot antipsychotic drugs in outpatients with schizophrenia in China.

Authors:  Y-T Xiang; Y-Z Weng; C-M Leung; W-K Tang; G S Ungvari
Journal:  Int J Clin Pharmacol Ther       Date:  2008-05       Impact factor: 1.366

7.  Psychotropic drug utilization in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project.

Authors:  J Alonso; M C Angermeyer; S Bernert; R Bruffaerts; T S Brugha; H Bryson; G de Girolamo; R Graaf; K Demyttenaere; I Gasquet; J M Haro; S J Katz; R C Kessler; V Kovess; J P Lépine; J Ormel; G Polidori; L J Russo; G Vilagut; J Almansa; S Arbabzadeh-Bouchez; J Autonell; M Bernal; M A Buist-Bouwman; M Codony; A Domingo-Salvany; M Ferrer; S S Joo; M Martínez-Alonso; H Matschinger; F Mazzi; Z Morgan; P Morosini; C Palacín; B Romera; N Taub; W A M Vollebergh
Journal:  Acta Psychiatr Scand Suppl       Date:  2004

Review 8.  Chlorpromazine equivalent doses for the newer atypical antipsychotics.

Authors:  Scott W Woods
Journal:  J Clin Psychiatry       Date:  2003-06       Impact factor: 4.384

9.  Chlorpromazine equivalents versus defined daily doses: how to compare antipsychotic drug doses?

Authors:  Claudia A W Rijcken; Taco B M Monster; Jacobus R B J Brouwers; Lolkje T W de Jong-van den Berg
Journal:  J Clin Psychopharmacol       Date:  2003-12       Impact factor: 3.153

10.  Drug utilization study of psychotropic drugs in outdoor patients in a teaching hospital.

Authors:  K G Piparva; D M Parmar; A P Singh; M V Gajera; H R Trivedi
Journal:  Indian J Psychol Med       Date:  2011-01
View more
  12 in total

1.  Dose Equivalents for Antipsychotic Drugs: The DDD Method.

Authors:  Stefan Leucht; Myrto Samara; Stephan Heres; John M Davis
Journal:  Schizophr Bull       Date:  2016-07       Impact factor: 9.306

2.  Antipsychotic drug dose in real-life settings results from a Nationwide Cohort Study.

Authors:  L Malandain; M Leygues; F Thibaut
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2021-08-22       Impact factor: 5.270

3.  Magnitude, Nature, and Risk Factors of Adverse Drug Reactions Associated with First Generation Antipsychotics in Outpatients with Schizophrenia: A Cross-Sectional Study.

Authors:  Merhawi Bahta; Tzeggai Berhe; Mulugeta Russom; Eyasu H Tesfamariam; Azieb Ogbaghebriel
Journal:  Integr Pharm Res Pract       Date:  2020-10-14

4.  Abnormalities in chemokine levels in schizophrenia and their clinical correlates.

Authors:  Suzi Hong; Ellen E Lee; Averria Sirkin Martin; Benchawanna Soontornniyomkij; Virawudh Soontornniyomkij; Cristian L Achim; Chase Reuter; Michael R Irwin; Lisa T Eyler; Dilip V Jeste
Journal:  Schizophr Res       Date:  2016-09-17       Impact factor: 4.939

5.  Translating Benzodiazepine Utilization Data into Meaningful Population Exposure: Integration of Two Metrics for Improved Reporting.

Authors:  Jaden Brandt; Wajd Alkabanni; Silvia Alessi-Severini; Christine Leong
Journal:  Clin Drug Investig       Date:  2018-07       Impact factor: 2.859

6.  Correspondence between negative symptoms and potential sources of secondary negative symptoms over time.

Authors:  Aida Farreny; Mark Savill; Stefan Priebe
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-06-02       Impact factor: 5.270

7.  Loneliness in schizophrenia: Construct clarification, measurement, and clinical relevance.

Authors:  Graham M L Eglit; Barton W Palmer; A'verria S Martin; Xin Tu; Dilip V Jeste
Journal:  PLoS One       Date:  2018-03-22       Impact factor: 3.240

8.  Antipsychotic prescribing patterns on admission to and at discharge from a tertiary care program for treatment-resistant psychosis.

Authors:  Lik Hang N Lee; Ric M Procyshyn; Randall F White; Todd S Woodward; William G Honer; Alasdair M Barr
Journal:  PLoS One       Date:  2018-08-10       Impact factor: 3.240

9.  Prevalence of and factors associated with antipsychotic polypharmacy in patients with serious mental illness: Findings from a cross-sectional study in an upper-middle-income country.

Authors:  Kerryn S Armstrong; Henk Temmingh
Journal:  Braz J Psychiatry       Date:  2017-02-06       Impact factor: 2.697

10.  Response to: A Commentary on "Antipsychotic-Induced Parkinsonism is Associated with Working Memory Deficits in Schizophrenia-Spectrum Disorders".

Authors:  Stéphane Potvin; Andràs Tikàsz
Journal:  Front Behav Neurosci       Date:  2015-08-12       Impact factor: 3.558

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.